WaveMan
WaveMan · Company
RCKT · Rocket Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RCKT Rocket Pharmaceuticals (RCKT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001281895
Quote by TradingView
Form 144 · 11
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
91
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $129.3K priced

What the filings say about RCKT

Insiders, 180 days
-$707.8K net sold
5 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$512.6K
11 notices

Rocket Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ROCKET PHARMACEUTICALS, INC. insiders sold a net $707.8K of stock across 118 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Wilson Martin
General Counsel
SELL
2026-09-15 SECtraded 2026-09-11
75,364
$256.5K
-34.5%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Aug 18, 2026.
  • The trade is 12.6% of the 598,489 shares held after it.
  • 1 other insider sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Wilson Martin sold about $256.5K of RCKT on Sep 11, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 91 funds added in the latest 13F quarter.
Shah Gaurav
CEO
SELL
2026-08-20 SECtraded 2026-08-18
2,293
$7.8K
-35.0%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (2 buys, 17 sales), the last on Aug 13, 2026.
  • -44.0% median (-44.0% mean) 90-day return after 2 previous buys.
  • The trade is 0.2% of the 1,056,594 shares held after it.
  • 3 other insiders sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Shah Gaurav sold about $7.8K of RCKT on Aug 18, 2026; 3 other insiders sold within 30 days and 91 funds added in the latest 13F quarter.
Wilson Martin
General Counsel
SELL
2026-08-20 SECtraded 2026-08-18
631
$2.1K
-35.0%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (17 sales), the last on Aug 13, 2026.
  • The trade is 0.1% of the 673,853 shares held after it.
  • 3 other insiders sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Wilson Martin sold about $2.1K of RCKT on Aug 18, 2026; 3 other insiders sold within 30 days and 91 funds added in the latest 13F quarter.
Wilson Martin
General Counsel
SELL
2026-08-17 SECtraded 2026-08-13
3,493
$11.8K
-31.7%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on May 19, 2026.
  • The trade is 0.5% of the 674,484 shares held after it.
  • 3 other insiders sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Wilson Martin sold about $11.8K of RCKT on Aug 13, 2026; 3 other insiders sold within 30 days and 91 funds added in the latest 13F quarter.
Shah Gaurav
CEO
SELL
2026-08-17 SECtraded 2026-08-13
2,837
$9.6K
-31.7%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (2 buys, 16 sales), the last on May 21, 2026.
  • -44.0% median (-44.0% mean) 90-day return after 2 previous buys.
  • The trade is 0.3% of the 1,058,887 shares held after it.
  • 3 other insiders sold within 30 days.
  • 91 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO Shah Gaurav sold about $9.6K of RCKT on Aug 13, 2026; 3 other insiders sold within 30 days and 91 funds added in the latest 13F quarter.
118 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 113 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$707.8K over 180 days
-$432.5K over 90 days
below 59% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
91 funds bought in last quarter
more than 65% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
17.2% of the float short (float per yahoo 2026-10-26) · 6.9 days to cover · settled 2026-09-30
more than 82% of Pharma & Biotech
The situation: each line is one rule over one dataset
2 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch RCKT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-39.0%12M
-42%-14%+14%+42%2025-102025-122026-022026-042026-062026-082026-10 2026-09-11 · Wilson Martin sold $256.5K2026-05-21 · Shah Gaurav sold $172.1K2026-08-11 · Stevens Christopher James sold $128.3K2026-05-07 · Chaudhuri Sarbani sold $67.8K2026-02-13 · Shah Gaurav sold $40.6K2026-02-13 · Wilson Martin sold $40.6K2026-01-02 · Bjork Elisabeth bought $34.4K2026-02-18 · Shah Gaurav sold $20.0K2025-11-18 · Shah Gaurav sold $18.7K2026-08-11 · Chaudhuri Sarbani sold $16.4K2026-02-13 · Militello John sold $12.3K2026-05-13 · Wilson Martin sold $12.1K2026-08-13 · Wilson Martin sold $11.8K2026-05-13 · Shah Gaurav sold $9.8K2026-08-13 · Shah Gaurav sold $9.6K2026-08-18 · Shah Gaurav sold $7.8K2025-11-18 · Schwartz Jonathan David sold $7.6K2026-05-19 · Shah Gaurav sold $7.3K2025-11-18 · Wilson Martin sold $4.9K2026-02-18 · Wilson Martin sold $4.6K2026-02-18 · Militello John sold $3.9K2025-11-18 · Militello John sold $3.2K2026-05-13 · Militello John sold $3.1K2026-08-18 · Wilson Martin sold $2.1K2026-05-19 · Wilson Martin sold $2.0K2026-05-19 · Militello John sold $1.2K2026-09-15 · Militello John filed to sell $22.7K2026-09-14 · Militello John filed to sell $22.7K2026-09-11 · Militello John filed to sell $30.4K2026-09-11 · Wilson Martin filed to sell $256.5K2026-08-18 · Militello John filed to sell $4.2K2026-08-18 · Wilson Martin filed to sell $2.1K2026-08-18 · Shah Gaurav filed to sell $7.8K2026-08-13 · Shah Gaurav filed to sell $9.6K2026-08-13 · Wilson Martin filed to sell $11.8K2026-08-11 · Chaudhuri Sarbani filed to sell $16.5K2026-08-11 · Stevens Christopher James filed to sell $128.3K2026-07-07 · Malik Fady Ibraham filed to sell $41.4K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RCKT: institutional holders (13F)

13F holdings, latest reported quarter
RTW INVESTMENTS, LP
18,037,772 sh
$60.5M
BlackRock, Inc.
9,923,962 sh
$33.9M
VANGUARD PORTFOLIO MANAGEMENT LLC
5,810,033 sh
$19.9M
CITIGROUP INC
4,865,551 sh
$16.6M
MARSHALL WACE, LLP
4,029,262 sh
$13.8M

Congress trades in RCKT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RCKT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Militello John
Filed 2026-09-15
$22.7K
Militello John
Filed 2026-09-14
$22.7K
Militello John
Filed 2026-09-11
$30.4K
Wilson Martin
Filed 2026-09-11
$256.5K
Militello John
Filed 2026-08-18
$4.2K

RCKT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$351.5K position · as of 2026-07-31
0.8%
AQR Small Cap Multi-Style Fund
$1.3M position · as of 2026-06-30
0.3%
Global X Genomics & Biotechnology ETF
$176.9K position · as of 2026-05-31
0.3%
NVIT Small Cap Value Fund
$536.3K position · as of 2026-06-30
0.2%
VANGUARD MARKET NEUTRAL FUND
$1.3M position · as of 2026-06-30
0.2%
Federated Hermes MDT Small Cap Growth Fund
$1.3M position · as of 2026-07-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
16 registered trials, 10 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
2 active
4
Phase 2
2 active
7
Not applicable
6 active
1
Multi-phase
0 active
What changed recently
A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
2026-10-07 · Completion moved 2028-04 → 2028-06
Phase 2
Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B
2026-10-07 · Completion moved 2025-03-24 → 2025-07-03
Phase 1
Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B
2026-10-07 · Unknown → Completed
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Mr. Shah
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$8.0M
$12.4M
$3.5M
+32%
+15%
2022
$6.6M
$5.2M
$2.7M
-14%
+11%
2021
$7.9M
-$4.3M
$3.6M
-4%
+25%
2020
$6.9M
$21.7M
$1.9M
+141%
+26%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $707.8K sold by insiders over 180 days, 91 funds added last quarter, $512.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RCKT financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$170.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-4.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-4.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-49.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-68.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0$0$0
Operating income-$231.7M-$273.2M-$259.7M-$224.3M
Net income-$223.1M-$258.7M-$245.6M-$221.9M
EPS (diluted)-2.01-2.73-2.92-3.26
Operating cash flow-$190.0M-$209.7M-$194.9M-$178.1M
Cash$77.6M$163.6M$55.9M$140.5M
SEC XBRL, fiscal years, as known on 2026-10-28

RCKT Stock Sonar score 4/7 axes

Find similar shapesCompare

RCKT ranks highest on profitability (70th percentile) and risk and compliance (45th), and lowest on insider conviction (19th), among Pharma & Biotech peers.

Profitability
70
Inputs
  • Return on equity-4.8% · 79 pct, sector of 545
  • Return on assets-4.1% · 79 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-49.8% · 50 pct, sector of 576
Insider conviction
19
Inputs
  • Net Form 4 buying (codes P and S), 180d-$708K · 38 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
42
Inputs
  • Funds adding, latest quarter91 · 65 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$90K · 19 pct, sector of 133
Risk and compliance
45
Inputs
  • Short interest, % of float+17.2% · 21 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.2% · 70 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RCKT filings, in plain words

Are Rocket Pharmaceuticals insiders buying or selling RCKT?

In the 180 days to 2026-10-28, Rocket Pharmaceuticals insiders were net sellers, a net $707.8K across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of RCKT?

Yes. 11 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $512.6K of stock; the latest, by Militello John, was filed 2026-09-15.

Read the full summary

In the 180 days to 2026-10-28, Rocket Pharmaceuticals insiders were net sellers of RCKT, a net $707.8K across purchases and sales reported on Form 4 by 5 sellers. None of the 15 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 11 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $512.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies